"Cell Line, Tumor" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A cell line derived from cultured tumor cells.
| Descriptor ID |
D045744
|
| MeSH Number(s) |
A11.251.210.190 A11.251.860.180
|
| Concept/Terms |
Cell Line, Tumor- Cell Line, Tumor
- Cell Lines, Tumor
- Line, Tumor Cell
- Lines, Tumor Cell
- Tumor Cell Lines
- Tumor Cell Line
|
Below are MeSH descriptors whose meaning is more general than "Cell Line, Tumor".
Below are MeSH descriptors whose meaning is more specific than "Cell Line, Tumor".
This graph shows the total number of publications written about "Cell Line, Tumor" by people in this website by year, and whether "Cell Line, Tumor" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 |
| 2002 | 0 | 1 | 1 |
| 2003 | 0 | 18 | 18 |
| 2004 | 0 | 57 | 57 |
| 2005 | 0 | 62 | 62 |
| 2006 | 1 | 57 | 58 |
| 2007 | 0 | 70 | 70 |
| 2008 | 1 | 79 | 80 |
| 2009 | 2 | 105 | 107 |
| 2010 | 0 | 88 | 88 |
| 2011 | 1 | 113 | 114 |
| 2012 | 2 | 90 | 92 |
| 2013 | 2 | 114 | 116 |
| 2014 | 0 | 130 | 130 |
| 2015 | 0 | 137 | 137 |
| 2016 | 0 | 153 | 153 |
| 2017 | 0 | 117 | 117 |
| 2018 | 0 | 141 | 141 |
| 2019 | 1 | 134 | 135 |
| 2020 | 0 | 119 | 119 |
| 2021 | 0 | 116 | 116 |
| 2022 | 0 | 40 | 40 |
| 2023 | 0 | 54 | 54 |
| 2024 | 0 | 100 | 100 |
| 2025 | 0 | 121 | 121 |
| 2026 | 0 | 58 | 58 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cell Line, Tumor" by people in Profiles.
-
Glioblastoma stem cell growth requires DOT1L-MED23 control of enhancer accessibility. Cell Rep. 2026 Jul 28; 45(7):117647.
-
KIF7 promotes the proliferation of clear cell renal cell carcinoma by activating the WNT/?-catenin signaling pathway. Clin Exp Med. 2026 Jun 28; 26(1).
-
Personalized targeting of BCL2 family proteins overcomes acquired resistance to BRAF-MEK inhibitors in preclinical melanoma. Nat Commun. 2026 Jun 26; 17(1).
-
Purinergic activity of circulating extracellular vesicles associates with disease progression in melanoma. Oncoimmunology. 2026 Dec 31; 15(1):2688603.
-
Morphology-dependent toxicity and MRI contrasting properties of Mn3O4 nanostructures: A comparative study. Biomater Adv. 2026 Nov; 188:215023.
-
Oncogenic KRAS-driven type I interferon signalling primes pancreatic cancer for necroptosis. Nat Commun. 2026 06 15; 17(1).
-
In Vivo ORF Overexpression Screening Identifies CCN4 as a Regulator of Glioblastoma Growth Validated Across Multiple Models. Int J Mol Sci. 2026 Jun 09; 27(12).
-
Histone deacetylase enzyme activity is not the universal anticancer target of HDAC inhibitors. Signal Transduct Target Ther. 2026 Jun 05; 11(1).
-
Overcoming menin inhibitor resistance in AML cells with combinations including BET proteins and a dual BRG1/BRM inhibitor. Blood. 2026 Jun 04; 147(23):2809-2820.
-
Coexpression of IL15 Promotes Effector Differentiation and Sustained Proliferative Capacity in ALPPL2-Specific Human CAR T Cells. Cancer Immunol Res. 2026 Jun 02; 14(6):933-943.